Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
- Resource Type
- Article
- Authors
- Zeissig, Sebastian; Rosati, Elisa; Dowds, C. Marie; Aden, Konrad; Bethge, Johannes; Schulte, Berenice; Wei Hung Pan; Mishra, Neha; Zuhayra, Maaz; Marx, Marlies; Paulsen, Maren; Strigli, Anne; Conrad, Claudio; Schuldt, Dörthe; Sinha, Anupam; Ebsen, Henriette; Kornell, Sabin-Christin; Nikolaus, Susanna; Arlt, Alexander; Kabelitz, Dieter
- Source
- Gut; Jan2019, Vol. 68 Issue 1, p25-39, 15p
- Subject
- T cell receptors
VEDOLIZUMAB
INFLAMMATORY bowel diseases
INTESTINAL diseases
- Language
- ISSN
- 00175749